IMUGENE LIMITED — Capital/Financing Update 2026

Feb 23, 2026

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Date: 24 February 2026

Notice of Expiry of Listed Options

Imugene Limited (ASX: IMU) (“Imugene” or “the Company”) advises that the attached letter and notice of exercise of options form has been sent to registered holders of the Company’s listed options (ASX: IMUO) (“Options”) advising that the Options which are exercisable at $0.43 each will expire at 5:00pm AEDT on Monday, 30 March 2026 (“Expiry Date”).

Official quotation of the Options on ASX will cease at close of trading on Tuesday, 24 March 2026, being four business days prior to the expiry date.

Holders of the Options can exercise all or part of their Options prior to the Expiry Date by providing the Company a completed notice of exercise of options form specifying the number of Options being exercised and the required payment of funds.

End

Release authorised by the Company Secretary of Imugene Limited.

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

communications@imugene.com

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (onCARlytics) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

IMUGENE LIMITED ACN 009 179 551

2

==> picture [178 x 31] intentionally omitted <==

24 February 2026

Dear Optionholder

Expiry of Listed Options (ASX: IMUO)

I am writing to you as a registered holder of IMUO listed options in Imugene Limited (ASX:IMU) ( Imugene or Company ) to remind you that the options will expire at 5:00pm (AEDT) on 30 March 2026 (Expiry Date).

Your option holding may be exercised in whole or in part by payment of $0.43 for each option in cleared funds prior to the Expiry Date. If payment is not received by the Expiry Date, the options will lapse and all rights under the options will cease at that time. On exercise, each IMUO option entitles the holder to:

If an Option is exercised, the following securities will be issued:

• a) one fully paid ordinary share (ASX:IMU); and

• b) one Piggyback Option (with an exercise price of $0.86 and expiry date of 30 June 2028.

There is no requirement for Optionholders to exercise their options. However, under paragraph 5.2 of Appendix 6A of the ASX Listing Rules the Company is required to advise Optionholders of the information contained in this notice.

The courses of action available to you as a holder of these options are as follows:

1. Exercise the options on or before the Expiry Date;

2. Sell your options. Quotation of the options will cease at the close of trading on Tuesday, 24 March 2026, being four business days before the Expiry Date; or

3. Allow the options to lapse . If payment in cleared funds is not received by the Expiry Date, the options will expire and all rights attaching to the Options will cease.

In accordance with Item 5.2 of Appendix 6A, the Company provides the following information to holders of the Options:

• a) This notice is being sent to all eligible Option Holders in accordance with clause 5.2 of Appendix 6A of the Listing Rules.

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

• b) the number of fully paid ordinary shares in the Company to be issued on the exercise and conversion of the Options is 56,678,780;

• c) the exercise price for each Option is $0.43 each (43 cents);

• d) the due date for payment of the exercise price is 5pm (AEDT) on Monday, 30 March 2026 (Expiry Date);

• e) if payment is not received by the Expiry Date, the Options will expire unexercised and all rights attaching to the Options will cease;

• f) official quotation of the Options on ASX will cease at close of trading on Tuesday, 24 March 2026, being four business days before the Expiry Date;

• g) the market price of the Company’s shares on Monday, 23 February 2026, was $0.25, (25 cents) being the latest available market price of shares on ASX prior to the date of this announcement;

• h) during the three months preceding the date of this announcement:

• the highest market price of the Company’s shares on ASX was $0.39 (39 cents) on 2 January 2026; and

• the lowest market price of the Company’s Shares on ASX was $0.24 (24 cents) on 6 February 2026; and

• i) as at the date of this announcement, there are no underwriting agreements in relation to the Options.

This letter is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser or other professional adviser.

An exercise form for the options is enclosed with this letter and full details of your holdings can be obtained from the Company’s share registry Automic at https://portal.automic.com.au/investor/home.

Should you have any queries in relation to this matter please contact the Company’s share registry, Automic Group, on +61 2 9698 5414 or Darren Keamy, Company Secretary at shareholderenquiries@imugene.com.

IMUGENE LIMITED ACN 009 179 551

2

All Registry Communication to:

Imugene Limited | ABN 99 009 179 551

PO Box 5193, Sydney NSW 2001 1300 288 664 (within Australia) +61 2 9698 5414 (international) hello@automic.com.au

==> picture [97 x 90] intentionally omitted <==

www.automicgroup.com.au

[EntityRegistrationDetailsLine1Envelope] [EntityRegistrationDetailsLine2Envelope] [EntityRegistrationDetailsLine3Envelope] [EntityRegistrationDetailsLine4Envelope] [EntityRegistrationDetailsLine5Envelope] [EntityRegistrationDetailsLine6Envelope]

SRN/HIN: [HolderNumberMasked] Security Code: IMUO Number of Options Held: [IMUOHolding] Option Expiry Date: 30 March 2026 Exercise Price: $0.43

NOTICE OF EXERCISE OF OPTIONS

NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS	NOTICE OF EXERCISE OF OPTIONS
I/we hereby exercise the following number of options and make payment in Australian currency for the amount payable. Please allot me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise. I/We agree to accept such Shares subject to the Constitution of Imugene Limited.
1.		Number of Options to be Exercised Total payment required @ $0.43 per Option exercised , , A$ , , .
					,				,						A$					,				,				.
		If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down.
2.		Payment by EFT
		Funds to be deposited directlyto the followingbank account: Account name: Imugene Limited Account BSB: 083004 Account number: 142729673 SWIFT code: NATAAU3303M IMPORTANT:When making your EFT payment please ensure that you use your registered holding name as your “payment description”. Failure to do so mayresult inyour funds not beingallocated toyour application and shares subsequentlynot issued. MP
3.		Contact details & signature
		Telephone Number Contact Name(PLEASE PRINT)
		( )
		Email Address
		SUPPORT YOUR COMPANY: By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).
Sign here:
Securityholder 1 Securityholder 2 Securityholder 3
Sole Director/Company Secretary Director Director / Company Secretary
NOTE: When signed under Power of Attorney, the attorney states that they have not received a notice of revocation. A certified copyof the Power of Attorneymust be lodged with this exercise form.
4. Submitting your “Notice of Exercise of Options” form
Please return the completed and signed form together with a copy of your funds transfer receipt:
BY MAIL Imugene Limited Level 12 4-6 Bligh Street Sydney NSW 2000 BY EMAIL shareholderenquiries@imugene.com